Program
ompekimig
Also written as “PF-07264660”, “PF-07264660 intravenous single ascending dose” and “PF-07264660 subcutaneous multiple ascending dose”.
In Pfizer's pipeline, anti-IL-4/ IL-13/ IL-33
. Its studies are mostly in Dermatitis, Atopic, led by Pfizer.
Furthest: phase 2, since Jul 26, 20233 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 31 open or running | phase 2since Jul 26, 2023 | Aug 9, 2022 | none ahead |
- Named in Pfizer’s own pipeline as
ompekimig
, phase 2, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2022First study: phase 1 study in HealthyFirst studyNCT05496738 · 59 enrolled · United States
- Jul 26, 2023Phase 2 study in Dermatitis, AtopicNCT05995964 · 507 enrolled · United States, Australia, Canada and more
- Nov 26, 2024Phase 1 study in HealthyNCT06712082 · 12 enrolled · China
Ahead
- Nov 12, 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT05995964
TargetBeta
“anti-IL-4/ IL-13/ IL-33”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06712082Healthy · China | 1 | Completed | Sep 4, 2025 | 12 |
| NCT05995964Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Active, not recruiting | Nov 12, 2026 | 507 |
| NCT05496738Healthy · United States | 1 | Completed | May 6, 2024 | 59 |
How it is read
Names in the registry
- “PF-07264660”, 2 entries
- “PF-07264660 intravenous single ascending dose”, 1 entry
- “PF-07264660 subcutaneous multiple ascending dose”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.